The Filing Desk

Opus Genetics vs ProQR Therapeutics

Opus Genetics IRD · ProQR Therapeutics PRQR · Pharmaceuticals

Opus Genetics reported revenue of $14 million in fiscal 2025, and ProQR Therapeutics €16 million in fiscal 2025, in different currencies. Opus Genetics' revenue grew 29.1% in its latest year, and ProQR Therapeutics' fell 15.9%. Opus Genetics had an operating margin of -271.9%, against -273.1% at ProQR Therapeutics.

Side by side

Opus GeneticsProQR Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$14M€16M
Revenue growth29.1%−15.9%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−271.9%−273.1%
Net margin−349.3%−265.2%
Free cash flow—−€54M
Free cash flow margin—−338.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M€0M
Change in diluted share count132.9%22.4%
Last close$4.08$1.05
P/E at the last close——
Insider trades, last 12 monthsbought $323,890, sold $16.6 million—
Piotroski F-score3 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
Opus GeneticsProQR Therapeutics
Operating margin
Percent of revenue
Opus GeneticsProQR Therapeutics
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
Opus GeneticsProQR Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Opus Genetics and ProQR Therapeutics pages.